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The Walter Hubert Lecture
Si SIGNALLING PATHWAYS DOWNSTREAM
OF SMALL GTPASES AS TARGETS FOR
THERAPY, C J Marshall, CRC Centre for Cell & Molecular Biology,
Institute ofCancer Research, 237 Fulham Road, London SW3 6JB.
The Ras proteins are involved in transmitting signals from
transmembrane growth factor receptors that result in cell proliferation.
Activation ofRas has been shown to be essential for growth factor
signalling (Marshall CJ, Cell 1995, 80: 179-185). In a sizable fraction
ofsome human tumours, particularly colon cancer and pancreatic
cancer, Ras proteins are mutated to a form which can generate
signalling in the absence ofgrowth factors. In tumours which contain
Ras oncogenes Ras is clearly a target for potential tumours but Ras
may also be a target in some other tumours because normal Ras
protein function is required for the proliferation of cells rendered
malignant by overexpressed receptor tyrosine kinases. Ras signalling
therefore presents an attractive targetfor therapeutic reagents that will
inhibit cell proliferation.
One approach to inhibit the function ofRas proteins is to block the
posttranslational modifications which are essential for p2IRas
function. This is exemplified by the farnesyltransferase inhibitors
(Gibbs JB, Cell 1994, 77: 175-8). The second approach is to identify
the signalling pathways activated by p21Ras and determine whether
these signalling pathways present targets for therapy. To date a
number ofsignalling pathways potentially activated by p21Ras have
been identified. The best characterised are the Raf/MAP kinase
pathway and the P13 kinase (Marshall CJ, Curr.Opion.Cell Biol. 1996,
8: 197-204). Studies from this laboratory have shown that the
Raf/MAP kinase pathway is essential for transformation of murine
fibroblasts with Ras or tyrosine kinase oncogenes. To extend these
studies to human tumours we have constructed retroviruses which can
be used to introduce mutated forms ofRaf/MAP kinase signalling
pathways into tumourcells inorder to block signalling in this pathway.
Studies with such vectors has shown that the malignant phenotypes of
a variety oftumour cells requires activation ofthe Raf/MAP kinase
pathway. These studies suggest that it is worth searching for small
molecule inhibitors of this pathway. Methods for screening such
inhibitors will be discussed.
S3 RAS-EFFECTOR INTERACTIONS, A. Wittinghoferl,
N. Nassarl, G. Horn', M. Geyer2, H.R. Kalbitzee?, C. Herrmann1, 1MPI
f. molekulare Physiologie, 44139 Dortmund/Germany, 2MPI f.
medizinische Forschung, 69120 Heidelberg/Germany
Ras is a major regulator of cell growth, which functions in many
signal transduction pathways coupling cell membrane receptor
activation to transcriptional events in the cell nucleus. In this process
Ras functions as a molecular switch which is activated from the GDP-
bound 'OFF'-state to the GTP-bound 'ON'-state. In the active form, its
interacts with downstream targets or effectors which are refined as
binding tightly to the GTP-bound form. This interaction is interrupted
by the GTPase reaction of Ras. In oncogenic mutants of Ras the
GTPase reaction is blocked which results in constant cell growth and
tumorformation.
Recently it has been shown that Ras interacts in a GTP-dependent
manner with several proteins, which are thus real or putative effectors
of Ras action. Mutations in Ras have been identified which weaken or
interrupt specifically the interaction with one or the other effector and
thus enabling us to selectively interrupt one of several potential Ras
signal transduction pathways. Thus it is becoming apparent that the
detailed atomic knowledge of the interaction of Ras with effector
proteins is necessary in order to understand the basis and selectivity
of signal transduction pathways originating from Ras. This information
could potentially be used as an approach towards developing anti-Ras
drugs.
In our laboratory the interaction between Ras and the effectors Raf-
kinase, Ral-GEF and Byr2 are being investigated at the biochemical,
structural and biological level. Recent findings will be discussed.
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Selective tyrosine protein kinase inhibitors.
S2 Nicholas B. Lydon, Elisabeth Buchdunger, Helmut Mett,
Marcel Muller, Robert Cozens, David Stover, Pascal Furet and Peter
Traxler. Oncology Research Department, Pharmaceuticals Division, Ciba-
Geigy Limited, CH-4002 Basel, Switzerland.
Using a calculated 3-D computer model of the kinase domain of the
epidermal growth factor receptor (EGF-R) tyrosine protein kinase (TPK), a
pharmacophore model for ATP-competitive kinase inhibitors was
developed. With the aid of this model, a series of 4-(phenylamino)-7H-
pyrrolo[2,3-d]pyrimidines were designed as inhibitors of the EGF-R and
shown to selectively inhibit the EGF-R TPK in vitro. CGP 59326, an
example ofthis class ofcompounds, is a potent and selective inhibitor ofthe
EGF-R TPK in vitro and in cellular assays. CGP 59326 did not significantly
inhibit other TPKs examined including the closely related pl85erbBM
kinase. CGP 59326 inhibited the proliferation of EGF-R expressing
epithelial cell lines in vitro (NCI-H596, BT-20, SK-BR-3, MDA-MB-468,
DU 145, A-431, BALB/MK), while having little antiproliferative activity
against EGF-R negative lines (NCI-H520, NCI-H69, NCI-H209, ZR-75-1,
HCT 116, FDC-PI). In contrast to previously described inhibitors, this
compound is characterized by potent and selective in vivo antitumor activity
at well tolerated doses (ED5O of 0.7-1.5 mg/kg for inhibition of A-431
tumor growth). When used as a single agenf, CGP 59326 inhibited growth of
human tumor xenografts expressing the EGF-R (MDA-MB468, NCI-H596,
A431), but showed little/no activity against EGF-R negative xenografts
(NCI-H520, BALB/c src). Combination of CGP 59326 with cytotoxic
agents resulted in tumor regression and cures, with different EGF-R positive
xenografts being sensitive to different drug combinations. Using the MDA-
MB-468 model, tumor regression and cures were obtained using CGP 59326
in combination with taxol, adriamycin and vinblastin. The high selectivity
and the attractive biological profile of CGP 59326 suggest that pyrrolo
pyrimidines could have therapeutic value in the treatment of proliferative
diseases which involve mitogenic signaling from the EGF-R.
S4 FARNESYLTRANSFERASE INHIBITORS AND ANTI-RAS
THERAPY,J. Gibbs *, A. Burkhardt', C.Buser', D.Heimbrook',
K. Koblan', N. Kohl', R. Lobell', C.Omer', T.Williams2, R. Barrington3, J. J. Windle3,
R.Mangues4, A. Pellicer4, S.Graham2, G. Hartman2, and A. OlifffDepts. of Cancer
Research' andMedicnal Chemistry2, Merck Research Laboratories, West Point, PA19486;
Cancer Therapy and Research Center3, San Antonio, TX 78229; Department of Pathology
and Kaplan CancerCenter4, NYU Medical Center, New York, NY 10016
The Ras oncogene protein is synthesized as a cytoplasmic precursor
which requires posttranslational processing to attainbiological activity. The
critical biochemical alteration that activates the Ras precursor protein is
farnesylation ofthecysteine residue within theCaaX motiflocated at the
carboxyl-terminus of all Ras proteins. Oncefamesylated and further modified,
themature Rasprotein is inserted intothecell's plasmamembrane where it
participates inthe signal transduction pathways that controlcell growth and
differentiation. Thefarnesylation reaction that modifies Ras and othercellular
proteins having anappropriateCaaX motif is catalyzed bya housekeeping enzymnetermd farnesyl-protein transferase(FPTase). We haveprepared
inhibitors ofthis enzyme in aneffort to identifycompounds thatblock Ras-
induced celltransformation and thereby functionasRas-specific antitumoragents.
Systematic modifications oftheseagents havecreated aseries ofhighly potent and
selective inhibitors of FPTase that do not inhibitgeranylgeranyl-protein
transferases. FPTase inhibitors block the growth of Ras-transformed cell lines in
tumorcolonyformingassays and themorphological alterationsassociated with
Ras-inducedtransformation ofmammalian cells m monolayer cultures. Whole
animal antitumor studies with two different structural classes ofinhibitors
(L-744,832and L-745,631) suggest that specificFPTase inhibitors may be useful
forthe treatment ofsometypesofcancer. Current studiesare focused ontheaction
ofFPTase inhibitors in several transgenic mousetumor models.2 Invited Papers
THE ANTIMETABOLITE RESURGENCE.
~ Robert C. Jackson, Agouron Pharmaceuticals Inc.,
San Diego, Califomia 92121, USA.
Antimetabolites have been regardedas inhibitors of macromolecular
biosynthesis that block cell replication by a process of competitive starvation. As
such, they have been considered as nonselective cytostatic agents that slow down
proliferation of transformed cells at the expense of severe myelosuppression and
gastrointestinal toxicity. According to this conventional wisdom, future
improvements are likely to be minor and quantitative. Despite an element of truth in
this position, it will be argued that a subset of antimetabolites are selectively
cytotoxic to transformed cells, that they kill slowly proliferating cells as well as
rapidly growing cells, and that they act, not by starving cell division through
depletion of precursors, but by selective induction of irreversible metabolic
perturbations in susceptible cells.
Recent years have seen the emergence of a cohort of new anticancer
antimetabolites- Pentostatin, fludarabine, Leustatin (2-CdA), gemcitabine, capcitabine,
trimetrexate, and Tomudex are now marketed drugs, while inhibitors of previously
unexplored target enzymes are in clinical trials. In other therapeutic areas, novel
antimetabolites are on the market or in development as antiviral, antiarthritic,
immunosuppressive and cardiovascular agents. This body of work has provided new
insights into effective ways of optimizing drug selectivity. Examples will be given
offour approaches.
Some new antimetabolites owe their selectivity to the optimization of
cellular pharmacokinetics. The ideal situation is for an active drug to be retained in
tumour cells for longer than in normal cell populations; this increases potency and
selectivity, and allows a cycle-specific drug to hit quiescent cells as they are recruited
into the cell cycle while cytotoxic drug levels remain within the cell. Tomudex is an
example of a drug that optimizes cellular pharmacokinetics. Another class of
antimetabolites acts primarily at feedback regulator- sites, and inducesirreversible
metabolic perturbations. 2-CdA probably acts at least partially through the binding of
its 5'-triphosphate to the dATP feedback site of ribonucleotide reductase.
Other antimetabolites cause perturbations that may be cytostatic or cytotoxic
depending on the checkpoint status of the cells. For example, AG2034, an inhibitor
ofglycinamide ribonucleotide formyltransferase, is cytostatic to cells with normal p53
function but selectively cytotoxic to cells that lackfunctional p53.
Finally, theoretical studies have raised the possibility of devising
antimetabolite combinations that are antagonistic in normal cells, but synergistic
against transformed cells (amphibolic combinations). These and other approaches
suggest that radically new ways of using antimetabolites may provide anticancer
regimens with greatly improved efficacy and selectivity. New clinical trial designs
will be needed, that make greater use of pharmacodynamic endpoints, and that are
conducted in patient subgroups whose tumours have defined molecular lesions.
S7 CLINICAL DEVELOPMENT OF TWO FOLATE-
BASED INHIBITORS OF THYMIDYLATE
SYNTHASE (TS) RALTITREXED (TOMUDEXR) AND ZD933 1 I. Judson,
TheInstitute ofCancer Research, Sutton, Surrey,SM2 5NG
Raltitrexed (TomudexR) is the first folate-based TS inhibitor to be licensed for
the treatment of cancer. It is a potent antitumour agent which is actively
transported via the reduced folate carrier (RFC) and concentrated in dividing
tissues due torapid and extensive polyglutamation, being an excellent substrate
for folyl polyglutamate synthetase (FPGS). Dose limiting toxicities in the UK
phase I trial, when given as a single 15 min infusion every 3 weeks, were
asthenia, myelosuppression and diarrhoea. A dose of 3.0 mg/r2 was
recommended for phase II evaluation. Raltitrexed showed promising activity
against breast and colorectal cancers. PhaseIII trials have confirmed similar
activity and palliative benefit to standard treatment with 5-FU + leucovorin in
advanced colorectal cancer, with less acute toxicity and the advantage of a
simpler, out-patient treatment schedule.The investigation ofdrug combinations
is underway. ZD9331 differs fromraltitrexed in that it is not polyglutamated,
which it is hoped will overcome drug resistance due to altered FPGS
expression, resulting in a different spectrum of antitumour activity, and may
also give a different toxicity profile. ZD9331 is currently in phase I trials
using a continuous infusion for 5 days (UK) and a short infusion daily for 5
days (USA), both every 3 weeks. A relatively short elimination half-life was
predicted from animal studies, unlike raltitrexed where an extremely prolonged
terminal elimination phase is observed, probably due to slow loss of drug
retained as polyglutamates. However, initial estimates ofterminal half-life are
in the region of3 days indicating that prolonged or frequent administration may
not be necessary. In the continuous infusion study patients have been treated
over the range 0.125 - 0.8 mg/m2/day and in the daily x 5 study from 0.4 to 1.6
mg/m2/day. Dose limiting toxicity has not been observed and the studies are
ongoing.
S6 THYMIDYLATE SYNTHASE (TS) INHIBITORS:
PRECLINICAL ASPECTS OF DISCOVERY AND
DEVELOPMENT. Ann L Jackman. CRC Centre for Cancer Therapeutics, the
Institute ofCancer Research, Sutton, Surrey.
Six new folate-based TS inhibitors have entered clinical studies in the last five
years. Drug design approaches have varied, which has resulted in the development
ofcompounds displaying different biochemical and pharmacological properties. For
example, Tomudexru (ZD1694, Raltitrexed) was designed, at Zeneca Pharmaceuticals and the Institute of Cancer Research (ICR), to take advantage of
the existence of a carrier-mediated, saturable cell membrane transporter, the
reduced-folate carrier (RFC), and the intracellular folate-metabolising enzyme,
folylpolyglutamate synthetase (FPGS). In this manner, moderately potent inhibitors
of isolated TS (e.g. ZD1694 Ki = 6OnM), that are good substrates for the RFC
(Km-2jsM), can be metabolised insidecells tovery potent TS inhibitors (ZD1694
tetraglutamate Ki =lnM) that are poor substrates for cellular efflux mechanisms.
ZD1694, because of its rapid intracellular polyglutamation, is active by infrequent
bolus schedules. A quite different approach to TS inhibitor design was taken by
Agouron Pharmaceuticals, whoseknowledge ofthe 3-D structure ofthe active site of
TS, led to the design of potent lipophilic, inhibitorsthat did not rely on cellular
transport proteins or FPGS for activity. ThymitaqTm (AG337; Ki =1lnM) has been
the most successful of the two drugs developed (the other being AG331) and has
completed PhaseII evaluation. As expected from a non-polyglutamatable drug,
AG337 is activeby continuous infusion or repeat bolus dosing. Zeneca and the ICR
have recently developed their second TS inhibitor (ZD933 1) which was designed to
be a highly water-soluble and very potent TS inhibitor (Ki=0.4nM), with activity
dependent on the RFC but independent ofFPGS. ZD933 1 is in Phase I evaluation.
Other companies also have TS inhibitors under study, for example Eli Lilly has
developed the polyglutamatable drug, LY231514, which, although lacking high
specificity for TS (also targets other folate-dependent enzymes), displayed good
activity in Phase II clinical trials. Glaxo-Wellcome has developed 1843U89 (in
Phase I study), acompound with some interesting properties; for example it is a very
potent TS inhibitor (Ki-O.lnM) that is an excellent substrate for FPGS. However,
the diglutamate is a poor substrate for FPGS, so that the major drug species is
diglutamate, which interestingly, is not more potent against TS than the parent
drug. Pre-clinical data can provide arguments for the relative advantages of one
profile compound over another, although it seems likely that their differences may
lead to activity in different tumour types, to the possession of non-identical toxicity
profiles, and to differing administration requirements.
S8 LY231514ANDAG337(THYMITAQm)-A
REVIEW OF CLINICAL ASPECTS. Hilary Calvert,
University ofNewcastle upon Tyne, UK.
LY 231514 is a classical antifolate which is readily converted into
polyglutamate forms. Although originally developed as a thymidylate
synthase inhibitor, it is now known to inhibit several folate-metabolising
enzymes inclulding dihydrofolate reductase and glycinamide ribonucleotide
formyltransferase although the relevance of these targets to its in vivo
activity remains unclear. Phase I studies have shown its toxicity to be
highly schedule dependent. Recommended PhaseII doses were 600 mg/mr2
for a single shot 4mg/Mr2/day for a five daily doses and 30 mg/mr2/week for
a weekly x 3 regimen. The dose-limiting toxicity was generally
myelosuppression (mainly neutropaenia) but gastrointestinal toxicity, skin
rashes and elevations of liver function tests were also seen. Responses in
colorectal cancer were seen in the single shot Phase I study and this
schedule is now being investigated in PhaseII trials.
AG 337 (THYMITAQm) is a non-classical thymidylate synthase
inhibitor, rationally designed from the crystal structure of thymidylate
synthase. Phase I studies were pharmacodynamically-controlled utilising the
plasma deoxyuridine level as a surrogate for in vivo inhibition of
thymidylate synthase. Because ofthe rapid elimination ofthe drug a five
day exposure period was necessary to induce biological effects. PET
scanning studies showed an increase in tumour incorporation of 'C
thymidine following administration of AG 337, evidence compatible with
thymidylate synthase being the in vivo locus of action of the drug. The
maximum tolerated dose was 1000 mg/in2/day. Phase II studies of a five
day continuous infusion showed activity in head and neck cancer and in
hepatoma - currently two randomised Phase II studies are under way in head
and neck cancer. AG 337 is readily bioavailable by the oral route so it may
be possible substitute oral administration forthe five day infusion.Invited Papers 3
GEMCITABINE: PRECLINICAL AND CLINICAL
S9 PROPERTIES, J. Carmichael, City Hospital, Nottingham
NG5 1PB
Gemcitabine (2'2'difluorodeoxycytidine - dFdC) is a new nucleoside
analogue with activity against a range of human tumours. It was originally
produced as a product of a screen for active agents against solid tumours
carried out by Eli Lilly USA.
dFdC is a prodrug which is activated intracellularly to its active
metabolites. It is phosphorylated via deoxycytidine kinase to its active forms
the di and triphosphate. It is metabolised by deamination. The metabolism
of dFdC is identical to ara C although there are marked differences in
metabolism and pharmacokinetics between the drugs that explain the
differences in activity against human solid tumours. dFdCTP is incorporated
into DNA causing DNA chain termination via inhibition of DNA polymerases.
The aberrant base appears to be relatively resistant to repair by proof
reading enzymes. There appear to be a number of mechanisms by which
the activity of dFdC appears to be self-potentiated, these include increased
activity of deoxycytidine kinase and decreased deamination. The drug was
shown to have significant activity in vitro against a wide range of cell lines
and subsequently in vivo against both murine and human tumour cell lines.
Pre-clinical studies inferred that the drug was strongly schedule dependant.
Clinical phase studies have been performed using a wide range of
schedules. A weekly schedule (days 1,8,15 every 28 days) was considered
the most appropriate to proceed into phase ll development. Gemcitabine
has been shown to have single agent activity against a wide range of human
cancers including NSCLC, breast, ovarian and bladder cancers. The drug is
well tolerated with minimal myelosuppression. The toxicity profile and its
mechanism of action as an inhibitor of DNA repair make it an ideal drug for
combination chemotherapy schedules. Excellent activity has been observed
with combinations ofdFdC with platinum drugs in particular.
Response rates of around 50% have been observed in a number of
studies in NSCLC. Likewise a combination of carboplatin and gemcitabine
has been shown to be active with -limited side effects. In breast cancer
combinations with anthracylines have shown significant activity.
Gemcitabine represents an interesting new cytotoxic drug that offers
opportunities forthe development of new combination chemotherapy
schedules for a variety of solid tumours.
The FrankRoseMemorialLture
Sl COUPLING DNA REPLICATION TO THE CELL CYCLE,
R.A. Laskey*, T. Krude, P. Romanowski, D. Coverley and
A.D. Mills, Wellcome/CRC Institute, Tennis CourtRoad,Cambridge CB2 1QR.
The initiation of DNA replication is a crucial decision point in
cell proliferation and therefore a potentially important target for
intervention. Furthermore it is the point at which many alternative
signal pathways converge, and therefore a more conserved aind general
target them the diverse network of signalling molecules themselves.
Initiation of replication has been notoriously difficult to study in
vitro. In this lecture, two cell-free systems that initiate replication in
vitro will be discussed with emphasis on their contributions to our
knowledge of the control of DNA replication and its coupling to the cell
cycle.
Eggs of the frog Xenopus laevis provided the first and most
widely studied system, yielding results that emphasise the importance of
nuclear structure, especially the nuclear membrane in replication control.
We have now developed a new system from cultured human cells.
It initiates replication in vitro in a cyclin and CDK-dependent way
allowing direct investigation of this crucial regulatory step.
sia ETHYNYLURACIL (776C 85, EU): A POTENT
MODULATOR OF 5FU ACTIVITY. G. Milano*, J.L.
Fischel, P. Formento, M.C. Etienne, Centre Antoine Lacassagne,
Nice, France
The first step in the catabolism of 5FU involves
dihydropyrimidine dehydrogenase (DPD). It has been previously
shown, both in vitro and in cancer patients, that tumoral DPD was
an independent factor significantly related to 5FU sensitivity: the
lower the DPD activity, the greater the 5FU sensitivity. These data
provide a strong pharmacological rationale opening the spectrum of
5FU modulation with the possibility of inhibiting DPD activity. EU is a
very potent mechanism-based irreversible DPD inactivator. From a
large panel of human cancer cell lines, it has been shown that
enhancement of 5FU cytotoxicity by EU (up to a factor of 5)
occurred in cell lines expressing the greatest basal DPD activity.
One hundred per cent of complete response were obtained with EU
associated with ftorafur in rats bearng colorectal carcinoma. A dual
5FU modulation was tested by combining 5FU with EU and folinic
acid (FA) on a panel of human cancer cell lines. In cell lines
responsive to 5FU modulation by FA and EU, the dual modulation
by FA + EU led to a synergistic interaction with a median value of
the global 5FU cytotoxicity enhancement factor at 6.3. Even though
these expermental data may not obligatory reflect in vivo results,
and particularly as regards a modification of the therapeutic index,
they may be useful for a better handling of drugs in the context of
the ongoing phase 11 trials on 5FU combined with EU.
S12 ACTIVATION OF P53IN RESPONSETO
DNA DAMAGE lo Milner, Andrei Okorokov,
Frederique Ponchel, YCRC p53 Research Group, Department of
Biology, University of York, York YO1 5DD, U.K.
The p53 protein is a naturally occuring tumour
suppressor which not only blocks the proliferation of
cells with DNA damage, but is also able to contribute
towards the process of DNA repair. The mechanism of
activation of p53 in response to DNA damage is
unknown. We have now shown that interaction with
"damaged" DNA in vitro induces proteolytic cleavage of
p53 (?autoproteolysis) to generate specific protein
fragments. Moreover, the pattern of p53 cleavage induced
in response to ssDNA differs from that induced by
dsDNA lesions such as ds breaks or insertion/deletion
mutations.
Studies in cells grown in culture demonstrate that
proteolytic cleavage induced by DNA damage activates
certain functions of p53, including transactivation of p21
expression, leading to Gl arrest and/or apoptosis. Other
functions of p53, such as (i) 3' to 5' exonuclease activity,
(ii) ssRNA and ssDNA re-annealing activity, and (iii)
repression of target gene expression are also activated (in
vitro studies). A model by which different types of DNA
damage may selectively activate different functions of p53
will be presented.4 Invited Papers
S13 INTERPLAY BETWEEN CYTOKINE SIGNALLING AND
ONCOGENE EXPRESSION IN THE CONTROL OF CELL VIABILITY
Gerard I. Evan*, Andrea Kauffmann-Zeh, Nicola McCarthy, Eugen
Ulrich and Moira Whyte, Imperial Cancer Research Fund Laboratories,
44, Lincoln's Inn Fields, London WC2A 3PX, UK.
Many diverse factors modulate mammalian cell apoptosis. These
include oncoproteins, tumour suppressor proteins, cell cycle regulators,
cytokines, toxins and physical trauma. However, how each of these
impacts upon what is believed to be a basal apoptotic machinery is
obscure. We have studied the induction of apoptosis in fibroblasts by
the oncoproteins c-Myc and ElA, both of which promote cell death
most effectively in the absence of the survival factor IGF-I. Suppression
of oncoprotein-induced apoptosis by IGF-I is independent of the cell
cycle, requires no de novo protein synthesis and its effect is exerted
almost instantaneously. To investigate further the mechanism by
which IGF-I suppresses apoptosis, we have taken two strategies. One is
to dissect the IGF-I receptor to identify regions of the molecule that
propagate survival signals. The second is to identify where within the
"hierarchy" of apoptosis control IGF-I exerts its effects. We can show
that IGF-I exerts an anti-apoptotic effect downstream of oncoproteins,
p53, the Bcl-2 family, and the pro-enzyme form of the cysteine protease
ICE. However, IGF-I does not suppress apoptosis induced by active
ICE. However, comparison of the anti-apoptotic effects of IGF-I with a
bona fide ICE protease inhibitor ZVAD.fmk indicates that IGF-I acts
upstream of activation of ICE proteases. Whereas IGF-I prevents the
onset of apoptosis, as judged by the start of membrane blebbing,
ZVAD.fmk has no effect on membrane blebbing but acts to prevent
completion of the apoptotic programme itself. Thus IGF-I acts prior to
the "apoptotic trigger" whereas active ICE proteases comprise part of
the actual apoptotic process itself.
S15 CHEMICAL INHIBITORS OF CYCLIN-DEPENDENT
KINASES Laurent MEIJER
CNRS, Station Biologique, B.P. 74, 29682 Roscoff cedex, France
Tel.: 33(0)2.98.29.23.39; Fax: 33(0)2.98.29.23.42; E-mail: meijer@sb-roscoff.fr
The cell division cycle is controled by a family of related cyclin-dependent
kinases (cdkl-8), which, in association with their cyclin partners (cyclin A-H), form
transiently active complexes. These complexes are finely regulated by various post-
translational modifications, such as phosphorylation/dephosphorylation, association
with regulatory proteins, interaction with inhibitory proteins, intracellular
translocations. Increasing evidence supports the importance of cyclin-dependent
kinases deregulation in the development of human tumours. Furthermore, several
examples illustrate the connection between cell cycle control mechanisms and
apoptosis. The search for chemical inhibitors of cyclin-dependent kinases and of
their regulators constitutes an important new approach for the discovery of novel
anti-tumour agents. We here describe the first generation of chemical inhibitors of
cyclin-dependent kinases. The G2/M transition of the cell cycle is triggered in all
organisms by a universal "M phase-Promoting Factor" (MPF), constituted of at least
two subunits, p34cdc2 (catalytic) and cyclinBcdcl3 (regulatory). This complex can be
purified by affinity chromatography on immobilized p9CKShs. The activity of the
p34cdC2/cyclinBcdc13 protein kinase is assayed, in the presence of potential inhibitors,
using histone HI and 32P-labelled ATP. This method has allowed the detection of
several potent inhibitors the properties of which will be reviewed. Among these are
olomoucine and roscovitine, two purines derived from 6-dimethylaminopurine.
Kinetic analysis of kinase inhibition reveals that olomoucine and roscovitine behave
as competitive inhibitors for ATP. The kinase specificity of these inhibitors was
investigated on more than 30 highly purified kinases: most kinases are not
significantly inhibited; only the cell cycle regulating cdc2/cyclin B, cdk2/cyclin A and
cdk2/cyclin E kinases, the brain cdk5/p25 kinase and ERK1 are substantially
inhibited by olomoucine and roscovitine. Structure-activity relationship studies allow
speculations on the interactions of olomoucine and roscovitine with the kinase
catalytic subunit. Analysis of olomoucine/cdk2 and roscovitine/cdk2 co-crystal
structures confirms that olomoucine and roscovitine bind in the ATP-binding pocket
of cdk2, but shows that the purine rings of olomoucine/roscovitine and ATP are
located in a totally different orientation. The anti-mitotic effects of olomoucine and
roscovitine were investigated in a large variety of cellular models. The compounds
inhibit both Gl/S and G2/M transitions. The effects of cyclin-dependent inhibitors
on apoptosis will be reviewed. We believe that the use of cell cycle control proteins
provides highly specific mechanism-based screens for the discovery of anti-mitotic
drugs of potential anti-tumour activity.
Meijer, L., 1996. Chemical inhibitors of cyclin-dependent kinases. Trends in Cell
Biology 6, 393-397.
S14 Telomerase as a NovelTherapeutic Targetfor
Cancer. E.Kenneth Parkinson
Beatson Institute for CancerResearch, CRC Beatson Laboratories, Garscube
Estate, Switchback Rd., Bearsden, Glasgow G61 1BD UK.
The cells of the germ line of humans are immortal but in contrast most of
the somatic cells undergo replicative senescence culminating in cell cycle arrest.
It has been proposed that -the repeat sequences found at the end of the
chromosomes, the telomeres, will gradually shorten because of the end replication
problem unless a special enzyme, telomerase, is present to correct the loss.
Indeed, it has been proposed that telomere loss forms the basis of the replicative
senescence clock. More recent evidence suggests thattelomerase is switched off in
most human somatic cells thus rendering them vulnerable to telomeric attrition
and senescence but the rate at which these linked processes occur may also be
influencedby theenvironment and mostespecially byoxidative damage.
Most advanced human cancers are composed of immortal cells that have
abrogated the process of replicative senescence. These cells usually possess
critically short telomeres and high levels of telomerase. Furthermore, the
immortal cells of human cancers and a large subset of in vivo cancers harbour
genetic alterations that are consistent with the deregulation of the senescence
process, including telomerase. Since the telomeres of many human cancer cells
are critically short they are believed to be time-expired cells that are heavily
dependent on telomerase for their survival. In contrast, normal cells have long
telomeres, even in old individuals, and do not appear to require telomerase to
survive. Telomerase could, therefore, be a novel and highly selective anticancer
target and the evidencefor and against this possibilitywill bediscussed.
The BACR/Zeneca Young Scientist ofthe
YearAward Lecture
MOLECULARCONTROLOF CELLULARINVASIONIN
COLORECTAL CANCER CELLS: THE ROLE OF TYROSINE
KINASES. VG Brunton', C Paraskeva2 and MC Frame', 'The Beatson Ilstitute for
Cancer Researh, Switchback Road, Bearsden, Glasgow, G61 IBD and Department of
Pathology andMicrobiology, UniversityofBristol,Bristol, BS8 lTD.
We have identified potential mediators of the behavioural changes which
accompany the development of colon cancer. In particular, the epidermal
growth factor (EGF) receptor and the focal adhesion kinmase (ppl25FAK),
molecules which are known to functionally co-operate with the Src fmily
kinases, are elevated during the conversion ofa pre-malignant colon adenoma
cell line to a malignant colon carcinoma cell line in vitro. EGF induced the
movement of the carcinoma cells into reconstituted basement membrane
Mgatigel in an in vitro imvasion assay which was not seen with the
premalignant adenoma cells. EGF did not alter the growth ofeither cell line.
The increased motility was accompanied by an EGF-induced relocalisation of
c-Src to discrete areas at the cell periphery and tyrosine phosphorylation of
ppl25FAK in the carcinoma cells but not the adenoma cells, suggesting that
these tyrosine kinases are components ofapathway whose mis-regulation may
contribute to colon cancer cell inasion. We also have a series of cell lines
derivedfrom a colonadenocarcinoma andlymphand hepatic metastas taken
from the same patient. In a wound healing assay hepatocyte growth factor
(IGF) induced the migration of the metastatic cells into the wound but not
those from the primary adenocarcnoma. This was dependent on the presence
of extracellular matrix components and was not due to proliferation at,the
wound edge. The HGF-induced movement of the metastatic cells could be
blocked by treatment with a Src tyrosine kinase inhibitor PD 162531, giving
further support for a role for Src kinases in growthfactor-induced cell motility.
We are currently using both molecular and pharmacological agents to dissect
further the pathways involved in growth factor-induced colon tumour cell
motilityandinvasion.